Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines

HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18
(ots/PRNewswire) --

Agendia, a world leader in molecular cancer diagnostics, today
announced that its signature breast cancer tumor recurrence test,
MammaPrint(R), has been included in the updated 2008 guidelines of
The Dutch Institute for Healthcare Improvement CBO. The CBO
guidelines, which cover all areas of healthcare and have an important
role to play in the improvement of the quality of patient treatment
and care, were drafted in collaboration with the Dutch Association of
Comprehensive Cancer Centers (ACCC) and the Dutch National Breast
Cancer Consultation Group (NABON).

The inclusion of MammaPrint in CBO's updated clinical practice
guidelines represents a significant step forward for the role of
molecular diagnostics in breast cancer treatment planning.
Specifically, the new guidelines acknowledge the prognostic power of
MammaPrint in general and highlight its ability to identify subgroups
of untreated node negative patients as having a good or poor
prognosis. The test also allows physicians and patients to determine
with which therapy, if any, to address each individual patient's risk
profile, ultimately providing a significant benefit of more
personalized medicine. The Dutch guideline committee also encouraged
physicians to enter patients into the MINDACT trial to allow
establishing additional knowledge.

"We are delighted that MammaPrint has been included in the CBO
guidelines," said Bernhard Sixt, Ph.D., president and chief executive
officer of Agendia. "With a very high accuracy, MammaPrint identifies
patients who have a risk of developing metastases within five to
seven years after surgery. Therefore, the test is a very powerful
tool that allows physicians to assess the rationale of adjuvant
chemotherapy, which has been shown to be effective in reducing these
early events in a meta-analysis of studies that included 30,000
patients."

The Dutch Institute for Healthcare Improvement CBO was founded in
1979 by the Dutch Association of Medical Specialists and Dutch
Association of Chief Medical Officers, as an independent,
not-for-profit foundation devoted to improving the quality of patient
care in The Netherlands. The guidelines are available online at
www.cbo.nl and are published in the September/October issue of the
Journal of the Dutch Association of Medical Oncology.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first FDA cleared
(February 2007) DNA microarray-based 'in vitro diagnostic
multivariate index assay' (IVDMIA). MammaPrint(R) measures the
activity of 70 genes, providing information about the likelihood of
tumor recurrence. The MammaPrint(R) test measures the level of
expression of each of these genes in a sample of a woman's
surgically-removed breast cancer tumor and then uses a specific
formula or algorithm to produce a score that determines whether the
patient is deemed low risk or high risk for spread of the cancer to
another site. The result serves to help a doctor in planning
treatment and appropriate follow-up for a patient when used with
other clinical information and laboratory tests. All MammaPrint(R)
tests are conducted in Agendia's CLIA-certified central service
laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The
company markets four products based on its breakthrough platform for
tumor gene expression profiling, and has several new diagnostic tests
under development. Agendia was the first company to receive FDA
clearance for a breast cancer test, MammaPrint(R) that predicts the
risk of breast cancer recurrence. In addition, the company
collaborates with pharma companies to develop highly effective
personalized drugs in the area of oncology. Agendia is based in
Huntington Beach, California, and in Amsterdam, The Netherlands. For
more information on Agendia, please visit www.agendia.com.

MEDIA CONTACTS:
U.S. Media Contact:
Kelly Connor
Vice President
Ogilvy Public Relations Worldwide
+1-212-880-5328 Office
+1-609-221-5785 Mobile
Kelly.connor@ogilvypr.com
EU and non-US Media:
Hans Herklots
Head of Corporate Communications
Agendia
+31-20-462-1557 Office
+31-620-083-509 Mobile
hans.herklots@agendia.com
Web site: http://www.cbo.nl
http://www.agendia.com

ots Originaltext: Agendia BV
Im Internet recherchierbar: http://www.presseportal.de

Contact:
U.S. Media Contact: Kelly Connor, Vice President, Ogilvy Public
Relations Worldwide, for Agendia, +1-212-880-5328 Office,
+1-609-221-5785 Mobile, Kelly.connor@ogilvypr.com; or EU and non-US
Media: Hans Herklots, Head of Corporate Communications of Agendia,
+31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com